Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange

References

1. 1.↵
   2. Cha S,
   3. Knopp EA,
   4. Johnson G, et al

   . Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29 doi:10.1148/radiol.2231010594 pmid:11930044

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Aronen HJ,
   3. Gazit IE,
   4. Louis DN, et al

   . Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51 doi:10.1148/radiology.191.1.8134596 pmid:8134596

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Law M,
   3. Yang S,
   4. Wang H, et al

   . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98 pmid:14625221

   Abstract/FREE Full Text
4. 4.↵
   2. Law M,
   3. Oh S,
   4. Babb JS, et al

   . Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging–prediction of patient clinical response. Radiology 2006;238:658–67 doi:10.1148/radiol.2382042180 pmid:16396838

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Danchaivijitr N,
   3. Waldman AD,
   4. Tozer DJ, et al

   . Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 2008;247:170–78 doi:10.1148/radiol.2471062089 pmid:18372467

   CrossRefPubMed
6. 6.↵
   2. Boxerman JL,
   3. Ellingson BM,
   4. Jeyapalan S, et al

   . Longitudinal DSC-MRI for distinguishing tumor recurrence from pseudoprogression in patients with a high-grade glioma. Am J Clin Oncol 2014 Nov 26. [Epub ahead of print] pmid:25436828
7. 7.↵
   2. Gahramanov S,
   3. Varallyay C,
   4. Tyson RM, et al

   . Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncol 2014;3:389–400 doi:10.2217/cns.14.42 pmid:25438810

   CrossRefPubMed
8. 8.↵
   2. Schmainda KM,
   3. Zhang Z,
   4. Prah M, et al

   . Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol 2015;17:1148–56 doi:10.1093/neuonc/nou364 pmid:25646027

   Abstract/FREE Full Text
9. 9.↵
   2. Leu K,
   3. Enzmann DR,
   4. Woodworth DC, et al

   . Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging 2014;14:31 doi:10.1186/s40644-014-0031-z pmid:25608485

   CrossRefPubMed
10. 10.↵
    2. LaViolette PS,
    3. Cohen AD,
    4. Prah MA, et al

    . Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. Neuro Oncol 2013;15:442–50 doi:10.1093/neuonc/nos323 pmid:23382287

    Abstract/FREE Full Text
11. 11.↵
    2. Villringer A,
    3. Rosen BR,
    4. Belliveau JW, et al

    . Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med 1988;6:164–74 doi:10.1002/mrm.1910060205 pmid:3367774

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Meier P,
    3. Zierler KL

    . On the theory of the indicator-dilution method for measurement of blood flow and volume. J Appl Physiol 1954;6:731–44 pmid:13174454

    FREE Full Text
13. 13.↵
    2. Paulson ES,
    3. Schmainda KM

    . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601–13 doi:10.1148/radiol.2492071659 pmid:18780827

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Tofts PS,
    3. Kermode AG

    . Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging, 1: fundamental concepts. Magn Reson Med 1991;17:357–67 doi:10.1002/mrm.1910170208 pmid:2062210

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Roberts HC,
    3. Roberts TP,
    4. Brasch RC, et al

    . Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–99 pmid:10815665

    Abstract/FREE Full Text
16. 16.↵
    2. Ludemann L,
    3. Wurm R,
    4. Zimmer C

    . Pharmacokinetic modeling of Gd-DTPA extravasation in brain tumors. Invest Radiol 2002;37:562–70 pmid:12352165

    CrossRefPubMed
17. 17.↵
    2. Quarles CC,
    3. Gochberg DF,
    4. Gore JC, et al

    . A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation. Phys Med Biol 2009;54:5749–66 pmid:19729712

    CrossRefPubMed
18. 18.↵
    2. Donahue KM,
    3. Krouwer HG,
    4. Rand SD, et al

    . Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845–53 pmid:10861879

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Boxerman JL,
    3. Schmainda KM,
    4. Weisskoff RM

    . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859–67 pmid:16611779

    Abstract/FREE Full Text
20. 20.↵
    2. Ellingson BM,
    3. Cloughesy TF,
    4. Lai A, et al

    . Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:401–09 doi:10.1093/neuonc/noq206 pmid:21324937

    Abstract/FREE Full Text
21. 21.↵
    2. Burnham KP,
    3. Anderson DR

    . Model Selection and Inference: A Practical Information-Theoretic Approach. New York: Springer-Verlag; 1998
22. 22.↵
    2. Quarles CC,
    3. Ward BD,
    4. Schmainda KM

    . Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation. Magn Reson Med 2005;53:1307–16 pmid:15906288

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Schmiedeskamp H,
    3. Andre JB,
    4. Straka M, et al

    . Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI. J Cereb Blood Flow Metab 2013;33:732–43 doi:10.1038/jcbfm.2013.10 pmid:23462570

    Abstract/FREE Full Text
24. 24.↵
    2. Boxerman JL,
    3. Prah DE,
    4. Paulson ES, et al

    . The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. AJNR Am J Neuroradiol 2012;33:1081–87 doi:10.3174/ajnr.A2934 pmid:22322605

    Abstract/FREE Full Text
25. 25.↵
    2. Bjornerud A,
    3. Sorensen AG,
    4. Mouridsen K, et al

    . T1- and T2*-dominant extravasation correction in DSC-MRI, part I: theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab 2011;31:2041–53 doi:10.1038/jcbfm.2011.52 pmid:21505483

    Abstract/FREE Full Text
26. 26.↵
    2. Murase K

    . Efficient method for calculating kinetic parameters using T-1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med 2004;51:858–62 pmid:15065262

    CrossRefPubMedWeb of Science